IQVIA Holdings Inc. (IQV) Advances Clinical Research and Data Capabilities to Drive Growth

Core Insights - IQVIA Holdings Inc. is recognized as one of the best affordable growth stocks to buy now, with an Outperform rating and a price target of $221 set by RBC Capital [1][2] Group 1: Company Progress and Capabilities - The company is making significant strides in clinical trial activity and is expected to benefit from advancements in contract research organization and data analytics capabilities [2] - IQVIA holds over 64 petabytes of data and has established relationships with large pharmaceutical companies, which is seen as a critical differentiator in the market [2][3] Group 2: Technological Integration and Acquisitions - The integration and adoption of artificial intelligence in life sciences are anticipated to further enhance the company's outlook [3] - IQVIA has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories, which includes five sites for in vitro discovery services [3] Group 3: Industry Positioning - IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, focusing on improving healthcare outcomes through data, technology, and human expertise [4]